User:Mr. Ibrahem/Sucralfate
Clinical data | |
---|---|
Trade names | Carafate |
AHFS/Drugs.com | Monograph |
MedlinePlus | a681049 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, rectal |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 3-5% (local acting) |
Metabolism | GI; liver: unknown |
Elimination half-life | unknown |
Excretion | Feces, urine |
Identifiers | |
| |
Chemical and physical data | |
Formula | C12H54Al16O75S8 |
Molar mass | 2086.67 g·mol−1 |
(what is this?) (verify) |
Sucralfate, sold under various brand names, is a medication used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers.[3][4][5] Its usefulness in people infected by H. pylori is limited.[3] It is used by mouth and rectally.[3][5]
Common side effects include constipation.[3] Serious side effects may include bezoar formation and encephalopathy.[6] Use appears to be safe in pregnancy and breastfeeding.[6] How it works is unclear but is believed to involve binding to the ulcer and protecting it from further damage.[3][6]
Sucralfate was approved for medical use in the United States in 1981.[3] It is available as a generic medication.[6] In the United States the wholesale cost is about US$0.22 per dose.[7] In 2017, it was the 218th most commonly prescribed medication in the United States, with more than two million prescriptions.[8][9]
References[edit]
- ^ Merck Index, 12th Edition, 9049.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 22 January 2021. Retrieved 8 September 2020.
- ^ a b c d e f "Sucralfate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 2020-08-15. Retrieved 2019-04-08.
- ^ Maton PN (November 2003). "Profile and assessment of GERD pharmacotherapy". Cleveland Clinic Journal of Medicine. 70 Suppl 5: S51-70. doi:10.3949/ccjm.70.Suppl_5.S51. PMID 14705381.
- ^ a b Mendenhall WM, McKibben BT, Hoppe BS, Nichols RC, Henderson RH, Mendenhall NP (October 2014). "Management of radiation proctitis". American Journal of Clinical Oncology. 37 (5): 517–23. doi:10.1097/COC.0b013e318271b1aa. PMID 23241500. S2CID 12129192.
- ^ a b c d British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 73. ISBN 9780857113382.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
- ^ "Sucralfate - Drug Usage Statistics". ClinCalc. Archived from the original on 7 October 2020. Retrieved 11 April 2020.